Patheon unloads some assets on the way to an IPO

Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO. The company sold a plant in Capua, Italy, to German-headquartered industrial outfit Livia, getting rid of a facility that specializes in small molecules and enzymes. Separately, DPx, Patheon's parent company, sold off its agriculture and fine chemicals businesses to Ardian. Meanwhile, Patheon is preparing for a $100 million U.S. IPO. Livia deal | Ardian acquisition

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.